Bharat Biotech concludes phase 3 Covaxin trial, claims 77.8% efficacy against COVID 19

Hyderabad-based Bharat Biotech on Saturday concluded a final analysis for its vaccine Covaxin efficacy from phase-3 clinical trial claiming it to be 77.8 per cent effective against COVID-19. It also added that Covaxin gives 65.2 per cent protection against the SARS-CoV-2, B.1.617.2 Delta variant.

from IndiaTV India: Google News Feed https://ift.tt/3yjjB2J

Get Breaking news, Live news, and latest news from India and around the world on INDILIVENEWS.com, which are in the interest of nation and humanity. Like us on Facebook or Follow us on Twitter and Reddit for the latest news blog and live news update

Trending News

Loading...